Here, IVM, which acts as a positive allosteric modulator of P2X4R, is a U.S. Food and Drug Administration (FDA)-approved antiparasitic drug that enhances NLRP3 inflammasome signaling, while MnO2 alleviates tumor hypoxia to preserve eATP levels [14]. Here, NLRP3 is linked to neoplasm.